HER2 breast cancer biomarker detection using a sandwich optical fiber assay

被引:100
|
作者
Loyez, Mederic [1 ]
Lobry, Maxime [2 ]
Hassan, Eman M. [3 ,4 ]
DeRosa, Maria C. [3 ]
Caucheteur, Christophe [2 ]
Wattiez, Ruddy [1 ]
机构
[1] Univ Mons, Prote & Microbiol Dept, Pl Parc 20, B-7000 Mons, Belgium
[2] Univ Mons, Electromagnetism & Telecommun Dept, Bld Dolez 31, B-7000 Mons, Belgium
[3] Carleton Univ, Inst Biochem, 1125 Colonel By Dr, Ottawa, ON K1S 5B6, Canada
[4] Natl Res Council Canada, Metrol Res Ctr, Ottawa, ON K1A 0R6, Canada
关键词
Optical fiber; Breast cancer diagnosis; HER2; Biomarker; Aptamers; Surface plasmon resonance; FILM THICKNESS; SENSITIVITY; SPR; MULTIMODE; GRATINGS; DESIGN; SENSOR;
D O I
10.1016/j.talanta.2020.121452
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Optical fiber-based surface plasmon resonance (OF-SPR) sensors have demonstrated high versatility and performances over the last years, which propelled the technique to the heart of numerous and original biosensing concepts. In this work, we contribute to this effort and present our recent findings about the detection of breast cancer HER2 biomarkers through OF-SPR optrodes. 1 cm-long sections of 400 mu m core-diameter optical fibers were covered with a sputtered gold film, yielding enhanced sensitivity to surface refractive index changes. Studying the impacts of the gold film thickness on the plasmonic spectral response, we improved the quality and reproducibility of the sensors. These achievements were correlated in two ways, using both the central wavelengths of the plasmon resonance and its influence on the bulk refractive index sensitivity. Our dataset was fed by additional biosensing experiments with a direct and indirect approach, relying on aptamers and antibodies specifically implemented in a sandwich layout. HER2 biomarkers were specifically detected at 0.6 mu g/mL (5.16 nM) in label-free while the amplification with HER2-antibodies provided a nearly hundredfold signal magnification, reaching 9.3 ng/mL (77.4 pM). We believe that these results harbinger the way for their further use in biomedical samples.
引用
收藏
页数:8
相关论文
共 50 条
  • [31] Applications of electrochemical analytical techniques in HER2 detection for breast cancer
    Li, Zhenghan
    Xue, Guoping
    Mei, Yu
    INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE, 2024, 19 (10):
  • [32] Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues
    Tantiwetrueangdet, Anchalee
    Panvichian, Ravat
    Wongwaisayawan, Sansanee
    Sueangoen, Natthaporn
    Lertsithichai, Panuwat
    MEDICAL ONCOLOGY, 2018, 35 (12)
  • [33] In situ detection of HER2:HER2 and HER2:HER3 protein-protein interactions demonstrates prognostic significance in early breast cancer
    Spears, Melanie
    Taylor, Karen J.
    Munro, Alison F.
    Cunningham, Carrie A.
    Mallon, Elizabeth A.
    Twelves, Chris J.
    Cameron, David A.
    Thomas, Jeremy
    Bartlett, John M. S.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (02) : 463 - 470
  • [34] Droplet digital PCR using HER2/EIF2C1 ratio for detection of HER2 amplification in breast cancer tissues
    Anchalee Tantiwetrueangdet
    Ravat Panvichian
    Sansanee Wongwaisayawan
    Natthaporn Sueangoen
    Panuwat Lertsithichai
    Medical Oncology, 2018, 35
  • [35] Comparing the Gene Xpert Breast Cancer RUO mRNA Assay with ER and HER2 Immunohistochemistry (IHC) for Rapid Biomarker Analysis
    Mugabe, Marcellin
    Andrici, Juliana
    Ho, Ken
    Wu, Natalie
    Rizo, Annnaliza
    Lai, Edwin W.
    Jodi, Weidler
    Wendy, Wong
    Bates, Michael
    Izimukwiye, Isabelle
    Muvunyi, Jean Baptiste
    Rugwizangoga, Belson
    Milner, Danny A.
    Brock, Jane
    MODERN PATHOLOGY, 2017, 30 : 60A - 60A
  • [36] Comparing the Gene Xpert Breast Cancer RUO mRNA Assay with ER and HER2 Immunohistochemistry (IHC) for Rapid Biomarker Analysis
    Mugabe, Marcellin
    Andrici, Juliana
    Ho, Ken
    Wu, Natalie
    Rizo, Annnaliza
    Lai, Edwin W.
    Jodi, Weidler
    Wendy, Wong
    Bates, Michael
    Izimukwiye, Isabelle
    Muvunyi, Jean Baptiste
    Rugwizangoga, Belson
    Milner, Danny A.
    Brock, Jane
    LABORATORY INVESTIGATION, 2017, 97 : 60A - 60A
  • [37] Nanoimmunoassay onto a screen printed electrode for HER2 breast cancer biomarker determination
    Patris, Stephanie
    De Pauw, Pieter
    Vandeput, Marie
    Huet, Joelle
    Van Antwerpen, Pierre
    Muyldermans, Serge
    Kauffmann, Jean-Michel
    TALANTA, 2014, 130 : 164 - 170
  • [38] Monitoring Value of Serum HER2 as a Predictive Biomarker in Patients with Metastatic Breast Cancer
    Zhang, Pengyu
    Xiao, Jun
    Ruan, Yingxin
    Zhang, Zhenzhen
    Zhang, Xuejun
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4667 - 4675
  • [39] Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer
    Ma, Cynthia X.
    Bose, Ron
    Gao, Feng
    Freedman, Rachel A.
    Telli, Melinda L.
    Kimmick, Gretchen
    Winer, Eric
    Naughton, Michael
    Goetz, Matthew P.
    Russell, Christy
    Tripathy, Debu
    Cobleigh, Melody
    Forero, Andres
    Pluard, Timothy J.
    Anders, Carey
    Niravath, Polly Ann
    Thomas, Shana
    Anderson, Jill
    Bumb, Caroline
    Banks, Kimberly C.
    Lanman, Richard B.
    Bryce, Richard
    Lalani, Alshad S.
    Pfeifer, John
    Hayes, Daniel F.
    Pegram, Mark
    Blackwell, Kimberly
    Bedard, Philippe L.
    Al-Kateb, Hussam
    Ellis, Matthew J. C.
    CLINICAL CANCER RESEARCH, 2017, 23 (19) : 5687 - 5695
  • [40] Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer
    Kong, Sun-Young
    Nam, Byung-Ho
    Lee, Keun Seok
    Kwon, Youngmee
    Lee, Eun Sook
    Seong, Moon-Woo
    Lee, Do Hoon
    Ro, Jungsil
    CLINICAL CHEMISTRY, 2006, 52 (08) : 1510 - 1515